A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations

Prior treatment

• Have protocol-defined toxicities within 28 days before the start of study treatment.
• Prior history of receiving targeted therapy with specific KRAS G12D inhibitors/degraders or pan-RAS inhibitors/degraders for KRAS G12D mutation.
• Has undergone major surgery within 28 days prior to the first dose of study drug.
• Have experienced a severe concurrent infection within 28 days prior to the first dose of study drug.
• Patients with concomitant diseases or conditions deemed by the Investigator likely to interfere with protocol compliance.

Other illness

• Have a second primary malignancy.
• Patients with known hypersensitivity to the study drug or any of its components.
• Patients with other severe and persistent underlying medical conditions as assessed by the Investigator.
• Have protocol-defined clinically significant cardiovascular diseases.
• Patients with dyspnea at rest secondary to complications of advanced malignancy, or requiring continuous oxygen therapy due to other medical conditions.
• Patients with active pulmonary tuberculosis (TB).
• Patients with a known history of interstitial lung disease (ILD).
• Patients with a known history of allogeneic solid organ transplantation or allogeneic hematopoietic stem cell transplantation.

Other

• Patients with symptomatic brain or leptomeningeal metastases.
• Prolonged QTcF interval.
• Patients with congenital or acquired immunodeficiency.
• Female patients in pregnancy or lactation period.
• Patients unwilling or unable to comply with protocol-specified procedures.

• Written informed consent obtained.
• Adult patients aged ≥ 18 years.
• Patients with histologically or cytologically confirmed locally advanced, unresectable, or metastatic solid tumors harboring the KRAS G12D mutations.
• Agree to provide available archived FFPE tumor tissue specimens or voluntarily accept pre-treatment tumor biopsy.
• Have RECIST 1.1-defined measurable lesions.
• Has a life expectancy of \> 3 months.
• ECOG performance status 0-1.
• Adequate marrow, liver and kidney function.
• Meet the study's specified contraceptive requirements.
• Meet protocol-specified washout period requirements.